瑞典医疗机构不良反应报告和监测研究

摘要/Abstract

摘要： 目的：探索研究瑞典医疗机构不良反应报告和监测的组织体系、法律依据、药物警戒系统特点，为我国开展医疗机构不良反应报告和监测工作提供参考。方法：根据瑞典药品管理局网站发布的法律法规文件、年度报告、工作信息，以及相关文献，对瑞典医疗机构药物警戒体系各要素进行分析。结果：瑞典在医疗机构报告和监测工作方面开展了诸多工作，建立了较为成熟的安全性监测体系。结论：我国可以借鉴瑞典相关工作经验，提高我国医疗机构不良反应报告和监测能力，提出优化国家药物不良反应中心和区域中心的职责分工、简化医务人员不良反应报告途径、建立基于医疗机构数据的主动监测系统的建议。
[关键词]

关键词: font-size:13.3333px, ">瑞典；医疗机构；不良反应报告；不良反应监测

Abstract: Objective： To explore the organization system， legal basis and characteristics of pharmacovigilance system of adverse drug reaction (ADR) reporting and monitoring in medical institutions in Sweden， so as to provide reference for ADR reporting and monitoring in medical institutions in China. Methods： Analyze the elements of pharmacovigilance system in Swedish medical institutions according to the laws and regulations， annual reports， work information published on the website of Swedish drug administration， and related literature. Results： Sweden has carried out a lot of work in the reporting and monitoring of medical institutions， and established a relatively mature safety monitoring system. Conclusion： China could learn from the experience of Sweden to improve the ADR reporting and monitoring ability of medical institutions， and this paper puts forward the suggestions of optimizing the division of responsibilities between National Center and regional center， simplifying the ADR reporting channels of medical staff， and establishing an active monitoring system based on the data of medical institutions.

Key words: font-size:13.3333px, ">Sweden； Medical institutions； Adverse reaction reports； Adverse reaction monitoring

中图分类号:

乌兰其其格, 杨悦. 瑞典医疗机构不良反应报告和监测研究[J]. 中国药物评价, 2021, 38(3): 255-258.

WU Lan-qiqige, YANG Yue. Adverse Reaction Reporting and Monitoring Research in Swedish Medical Institutions[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2021, 38(3): 255-258.

参考文献

[1]WHO. Members of the WHO Programme for International Drug Monitoring[EB/QL]. (2021-03-15) [2021-03-20]. https：//www. who-umc. org/global-pharmacovigilance/who-programme-for-international-drug-monitoring/who-programme-members/?id=100653&mn1=7347&mn2=7252&mn3=7322&mn4=7442
     [2]Swedish Medical Product Agency. The Medical Product Agency′s annual report 2020(in Swedish) [EB/QL]. (2021-02-22) [2021-03-06]. https：//www. lakemedelsverket. se/sv/nyheter/lakemedelsverkets-arsredovisning-for-2020-lamnad-till-regeringen.
     [3]Swedish Medical Product Agency. Investigator adverse reaction managementand signal detection/signal investigation (in Swedish) [EB/OL]. (2020-10-12) [2020-10-28]. https：//www. lakemedelsverket. se/sv/om-lakemedelsverket/jobba-pa-lakemedelsverket/lediga-jobb/utredare-biverkningshantering-och-signaldetektion-signalutredning.
     [4]M. Bckstrm， Elisabet Ekman， T. Mjrndal. Adverse drug reaction reporting by nurses in Sweden[J]. European Journal of Clinical Pharmacology， 2007， 63(6).
     [5]田春华，曹立亚. 瑞典药品不良反应监测系统[J]. 中国药物警戒， 2005，2(3)：187-189.
     [6]EC. REGULATION (EC) No 726/2004 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL[EB/QL]. (2012-11-14) [2021-01-06]. https：//ec. europa. eu/health/sites/health/files/files/eudralex/vol-1/reg_2004_726/reg_2004_726_en. pdf.
     [7]EC. Directive 2001/83/ec of the european parliament and of the council of 6 November 2001[EB/QL]. (2012-10-27) [2021-01-06]. https：//ec. europa. eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en. pdf
     [8]Swedish Medical Product Agency. The Medical Product Agency′s regulations(in Swedish) (LVFS 2012：14) om skerhetsvervakning av humanlkemede[EB/QL]. (2017-12-04) [2021-12-20]. https：//www. lakemedelsverket. se/4ad625/globalassets/dokument/lagar-och-regler/hslf-fs/lvfs-2012-14-konsoliderad. pdf
     [9]Swedish Medical Product Agency. What to report? (in Swedish) [EB/OL]. (2019-10-29) [2020-12-22]. https：//www. lakemedelsverket. se/sv/rapportera-biverkningar/lakemedel/rapporterna-bidrar-till-okad-kunskap.
     [10]Swedish Medical Product Agency. The Medical Product Agency′s annual report 2018(in Swedish) [EB/QL]. (2019-02-21) [2021-03-06]. https：//www. lakemedelsverket. se/4ae2a7/globalassets/dokument/publikationer/arsredovisning/lakemedelsverkets-arsredovisning-2018. pdf.
     [11]Swedish Medical Product Agency. Reporting of suspected adverse reactionsfrom health care systems (in Swedish) [EB/QL]. (2020-12-30) [2021-03-05]. https：//www. lakemedelsverket. se/sv/rapportera-biverkningar/lakemedel/misstankt-biverkning-hos-manniska/rapportering-fran-halso--och-sjukvardens-vardsystem.
     [12]Swedish Medical Product Agency. National reporting of suspected adverse drug reactions， NMBL (in Swedish) [EB/QL]. (2021-02-22) [2021-03-05]. https：//www. lakemedelsverket. se/sv/rapportera-biverkningar/lakemedel/misstankt-biverkning-hos-manniska/rapportering-fran-halso--och-sjukvardens-vardsystem/nationell-rapportering-av-misstankta-biverkningar-av-lakemedel-nmbl#hmainbody5.
     [13]Swedish Medical Product Agency. Handling of adverse reaction reports(in Swedish) [EB/OL]. (2019-10-29) [2020-20-22]. https：//www. lakemedelsverket. se/sv/rapportera-biverkningar/lakemedel/rapporterna-bidrar-till-okad-kunskap.
     [14]EMA. EudraVigilance system overview[EB/OL]. [2018-02-03]. http：//www. ema. europa. eu/ema/index. jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000166. jsp&mid=WC0b01ac0580a68f78.
     [15]Holm L， Ekman E， & Jorster Blomgren K. Influence of age， sex and seriousness on reporting of adverse drug reactions in Sweden. Pharmacoepidemiology and Drug Safety， 2017，26(3)， 335-343.
     [16]National Board of Health and Welfare. The Swedish Cancer Register [EB/OL]. (2019-05-29) [2020-01-20]. https：//www. socialstyrelsen. se/en/statistics-and-data/registers/register-information/swedish-cancer-register/.
     [17]National Board of Health and Welfare. The Swedish Medical Birth Register[EB/OL]. (2019-05-29) [2020-01-20]https：//www. socialstyrelsen. se/en/statistics-and-data/registers/register-information/the-swedish-medical-birth-register/.
     [18]Bjrn Wettermark， Niklas Hammar， Carl Michael Fored. The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months[J]. Pharmacoepidemiology and Drug Safety， 2007， 16(7)：726-735.
     [19]National Board of Health and Welfare. The Swedish Prescribed Drug Register [EB/OL]. (2020-08-21) [2021-01-20]https：//www. socialstyrelsen. se/en/statistics-and-data/registers/register-information/the-swedish-prescribed-drug-register/.
     [20]National Board of Health and Welfare. The Swedish Prescribed Drug Register-provides reliable facts about prescription medicines(in Swedish) [EB/OL]. [2021-04-06]. https：//www. socialstyrelsen. se/globalassets/sharepoint-dokument/dokument-webb/ovrigt/halsodataregister-lakemedelsregistret-nyttan-med-register. pdf.
     [21]Susanna M Wallerstedt， Bjrn Wettermark， Mikael Hoffmann. The First Decade with the Swedish Prescribed Drug Register-A Systematic Review of the Output in the Scientific Literature[J]. Basic & Clinical Pharmacology & Toxicology， 2016， 119(5)：464-469.